Cidara Therapeutics Stock News

Gainers ObsEva SA (NASDAQ: OBSV) rose 93.1% to $0.2047 in pre-market trading after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switz

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for

Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for pat

Today, we are putting the spotlight on small biotech concern Cidara Therapeutics for the first time in more than a year and a half. The company has an impressive set of collaboration deals with larger

FDA decision expected by PDUFA target action date of March 22, 2023

Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets. Genius Group Limited (NYSE: GNS) shares jumpe

CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target

Rezafungin has an FDA approval deadline of March 22, 2023. The stock has been neglected by investors.

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patien

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for p

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patien